393509-04-1

Basic information

• Product Name: Cyclopent[b]indole-3-acetic acid, 5-bromo-4-[(4-chlorophenyl)methyl]-7-fluoro-1,2,3,4-tetrahydro-
• CAS NO: 393509-04-1
• Molecular Formula: C20H16BrClFNO2
• Molecular Weight: 436.708
• Mol File: 393509-04-1.mol
• Article Data: 11

Chemical Properties

• CAS DataBase Reference: Cyclopent[b]indole-3-acetic acid, 5-bromo-4-[(4-chlorophenyl)methyl]-7-fluoro-1,2,3,4-tetrahydro-(CAS DataBase Reference)
• NIST Chemistry Reference: Cyclopent[b]indole-3-acetic acid, 5-bromo-4-[(4-chlorophenyl)methyl]-7-fluoro-1,2,3,4-tetrahydro-(393509-04-1)
• EPA Substance Registry System: Cyclopent[b]indole-3-acetic acid, 5-bromo-4-[(4-chlorophenyl)methyl]-7-fluoro-1,2,3,4-tetrahydro-(393509-04-1)

Safety Data

• Hazardous Substances Data: 393509-04-1(Hazardous Substances Data)

Upstream product

• 61272-76-2 4-fluoro-2-iodoaniline 
• 393509-23-4 (5-bromo-7-fluoro-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid 
• 186581-53-3 diazomethane 
• 622-95-7 4-chlorobenzyl bromide 
• 571170-85-9 (5-bromo-7-fluoro-1,2,3,4-tetrahydro-cyclopenta[b]indol-3-yl)-acetic acid methyl ester 
• 104-83-6 1-Chloro-4-(chloromethyl)benzene 
• 371-40-4 4-fluoroaniline 
• 1003-98-1 2-bromo-4-fluoroaniline 
• 20826-94-2 ethyl (2-oxocyclopentyl)acetate 
• 571170-84-8 [2-(2-bromo-4-fluoro-phenylimino)-cyclopentyl]-acetic acid ethyl ester 
• 393509-22-3 (+/-) 2-(7-fluoro-1,2,3-trihydrocyclopenta[2,3-b]indol-3-yl)acetic acid 
• 923580-07-8 (2E)-[5-bromo-4-(4-chlorobenzyl)-7-fluoro-1,4-dihydrocyclopenta[b]indol-3(2H)-ylidene]acetic acid 
• 393509-21-2 ethyl (7-fluoro-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetate 

Downstream Products

• 393509-05-2 [(3R)-5-bromo-4-(4-chlorobenzyl)-7-fluoro-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]acetic acid 
• 923580-07-8 (2E)-[5-bromo-4-(4-chlorobenzyl)-7-fluoro-1,4-dihydrocyclopenta[b]indol-3(2H)-ylidene]acetic acid 
• 571170-89-3 [5-bromo-4-(4-chloro-benzyl)-7-fluoro-1,2,3,4-tetrahydro-cyclopenta[b]indol-3-yl]-acetic acid methyl ester 
• 936337-07-4 methyl [(3R)-4-(4-chlorobenzyl)-7-fluoro-5-acetyl-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]acetate 
• 794535-36-7 [5-acetyl-4-(4-chloro-benzyl)-7-fluoro-1,2,3,4-tetrahydro-cyclopenta[b]indol-3-yl]-acetic acid 
• 571170-92-8 [4-(4-chloro-benzyl)-7-fluoro-5-methanesulfonyl-1,2,3,4-tetrahydro-cyclopenta[b]indol-3-yl]-acetic acid methyl ester 
• 571170-77-9 laropiprant 
• 393509-24-5 C₁₂H₁₃N*C₂₀H₁₆BrClFNO₂ 
• 878886-58-9 C₁₂H₁₃N*C₂₀H₁₆BrClFNO₂ 

Relevant articles and documents

Method of Treating Pathological Blushing

A method of treating pathological blushing is disclosed wherein the patient is administered a DP receptor antagonist. Compositions containing DP antagonists are also included.

METHOD OF TREATING ATHEROSCLEROSIS, DYSLIPIDEMIAS AND RELATED CONDITIONS

A method of treating atherosclerosis, dyslipidemia and related conditions is disclosed wherein a compound of formula I: or a pharmaceutically acceptable salt or solvate thereof is administered to the patient in combination with a DP receptor antagonist. T

NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT

The present invention encompasses compounds of Formula (I); as well as pharmaceutically acceptable salts and hydrates thereof, that are useful for treating dyslipidemias. Pharmaceutical compositions and methods of use are also included.